Johnson Covid 19- Vaccine at a vaccination center in Chicago, Illinois on March 5th, 2021.
The news that the Johnson Johnson vaccine would be paused seemed to take the wind out of the stock market on Tuesday, but many Wall Street analysts argued that the development did not change the overall direction for U.S. vaccination trends.
And individual company analysts argued it could be a buyer opportunity for competitors and some other related shares.
On Tuesday, the Food and Drug Administration and the Centers for Disease Control and Prevention recommended a pause in Johnson Johnson's Covid-19- vaccine citing a rare number of blood clot events following the jab. Health officials said they expected the pause to last for several days.